



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005
Current Effective Date: 01/15/2014

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors is addressed in medical policy 00175.

When Services Are Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider the use of radiofrequency ablation (RFA) of primary hepatocellular carcinoma (HCC) as a primary treatment of hepatocellular carcinoma (HCC) for patients when there are no more than three nodules and all tumor foci can be adequately treated to be **eligible for coverage** (see Clinical Guidelines).

Based on review of available data, the Company may consider the use of radiofrequency ablation (RFA) of primary hepatocellular carcinoma (HCC) as a bridge to transplant, where the intent is to prevent further tumor growth and to maintain a patient's candidacy for liver transplant to be **eligible for coverage**.

Based on review of available data, the Company may consider the use of radiofrequency ablation (RFA) as a primary treatment of hepatic metastases 5 cm or less in diameter from (CRC) in the absence of extrahepatic metastatic disease when all tumor foci can be adequately treated to be **eligible for coverage** (see Clinical Guidelines).

Based on review of available data, the Company may consider the use of radiofrequency ablation (RFA) as treatment of hepatic metastases from neuroendocrine tumors in patients with symptomatic disease when systemic therapy has failed to control symptoms to be **eligible for coverage** (see Clinical Guidelines).

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of radiofrequency ablation (RFA) of primary hepatocellular carcinoma (HCC) when there are more than three nodules or when not all sites of tumor foci can be adequately treated to be **investigational.***

Based on review of available data, the Company considers the use of radiofrequency ablation (RFA) of primary hepatocellular carcinoma (HCC) when used to downstage (downsize) hepatocellular carcinoma (HCC) in patients being considered for liver transplant to be **investigational.***

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

Based on review of available data, the Company considers the use of radiofrequency ablation (RFA) for hepatic metastasis to be **investigational*** for the following indications:

- For hepatic metastases from colorectal cancer (CRC) or neuroendocrine tumors that do not meet the criteria above; and
- For hepatic metastases from other types of cancer with the exception of colorectal cancer (CRC) or neuroendocrine tumors.

Clinical Guidelines

Explicit criteria have not been established for radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) or cancer metastatic to the liver.

For the eligible for coverage indications noted above for radiofrequency ablation (RFA) in those with primary hepatocellular carcinoma (HCC) and metastatic colorectal or neuroendocrine tumors, patients should not be candidates for curative resections (e.g., due to location of lesion(s) and/or comorbid conditions) and for hepatocellular carcinoma (HCC) should also not be candidates for liver transplantation.

Candidacy for radiofrequency ablation (RFA) treatment of hepatocellular carcinoma (HCC) is based on several factors that include number of tumor foci (nodules), size of tumor foci, and accessibility. In general, the randomized trials for hepatocellular carcinoma (HCC) have included patients with three or fewer hepatic lesions measuring 5 cm or less (and often 3 cm or less) using current technology.

Candidacy for radiofrequency ablation (RFA) treatment of metastatic colorectal cancer (CRC) or is based on several factors that include number of tumor foci, size of tumor foci, and accessibility. In general, published studies with metastatic colorectal cancer (CRC) have included patients with 4-5 or fewer hepatic lesions measuring 5 cm or less using current technology.

Background/Overview

In RFA, a probe is inserted into the center of a tumor and the noninsulated electrodes, which are shaped like prongs, are projected into the tumor; heat is generated locally by a high frequency, alternating current that flows from the electrodes. The local heat treats the tissue adjacent to the probe, resulting in a 3- to 5-cm sphere of dead tissue. The cells killed by RFA are not removed but are gradually replaced by fibrosis and scar tissue. If there is local recurrence, it occurs at the edge, and in some cases may be retreated. Radiofrequency ablation may be performed percutaneously, laparoscopically, or as an open procedure.

Hepatic tumors can arise either as primary liver cancer (HCC) or by metastasis to the liver from other tissues. Local therapy for hepatic metastasis may be indicated when there is no extrahepatic disease, which rarely occurs for patients with primary cancers other than CRC or certain neuroendocrine malignancies. At present, surgical resection with adequate margins or liver transplantation constitutes the only treatments available with demonstrated curative potential. However, the majority of hepatic tumors are unresectable at diagnosis, due either to their anatomic location, size, number of lesions, or underlying liver reserve.

Neuroendocrine tumors are tumors of cells that possess secretory granules and originate from the neuroectoderm. Neuroendocrine cells have roles both in the endocrine system and the nervous system.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

They produce and secrete a variety of regulatory hormones, or neuropeptides, which include neurotransmitters and growth factors. Overproduction of the specific neuropeptides produced by the cancerous cells causes a variety of symptoms depending on the hormone produced. They are rare, with an incidence of 2-4 per 100,000 per year. Treatment of liver metastases is undertaken to prolong survival and reduce endocrine-related symptoms as well as symptoms related to the hepatic mass.

Radiofrequency ablation has been investigated as a treatment for unresectable hepatic tumors, both as primary treatment and as a bridge to liver transplant. In the latter setting, it is hoped that RFA will reduce the incidence of tumor progression while awaiting transplantation, and thus maintain a patient's candidacy for liver transplant during the wait time for a donor organ. This issue has become less problematic with additional priority now assigned for patients with stage T2 hepatocellular cancer.

Various locoregional therapies for unresectable liver tumors have been investigated, including: RFA, cryosurgical ablation (cryosurgery), laser ablation, trans-hepatic artery embolization/ chemoembolization (TACE), microwave coagulation, percutaneous ethanol injection (PEI), and radioembolization (Yttrium-90 microspheres).

Rationale/Source

Radiofrequency Ablation as a Primary Treatment of Unresectable Hepatocellular Liver Cancer

Systematic Reviews: A 2003 Technology Evaluation Center (TEC) Assessment addressed RFA in the treatment of unresectable primary or metastatic liver tumors.

One of the first methods devised to ablate liver tumors involved PEI. Several nonrandomized trials in the 1990s confirmed that PEI could safely achieve complete necrosis in small HCCs, with 5-year survival rates of 32-38%. However, the technique had several drawbacks, including the need for multiple treatment sessions and a high local progression rate of 17-38%. Several randomized controlled trials (RCTs) have compared PEI and RFA in the treatment of small HCC. A systematic review of randomized trials for HCC treated with percutaneous ablation therapies was conducted by Cho and colleagues. The authors identified 4 RCTs involving 652 patients that compared RFA with PEI. The review concluded that RFA demonstrated significantly improved 3-year survival in patients with HCC compared to ethanol injections. The majority of patients in these studies had one tumor, and more than 75% of the tumors were 3 cm or smaller in size. The 3-year survival with RFA ranged from 63 to 81%.

In a 2013, Shen and colleagues reported on a meta-analysis of 4 RCTs and quasi-RCTs, totaling 766 patients, to compare RFA to PEI for treatment of HCC nodules up to 3 cm. Overall survival (OS) was significantly longer for RFA than PEI at 3 years (hazard ratios [HR]: 0.66, 95% confidence interval [CI]: 0.48-0.90, $p = 0.009$), and local recurrence risk was lower with RFA (HR: 0.38, 95% CI: 0.15-0.96, $p = 0.040$). However, there was no difference in distant intrahepatic recurrence and RFA resulted in more complications.

In 2012, Xu et al. reported on a meta-analysis of 13 studies to compare RFA to surgical resection for early HCC. Only 2 of the studies were RCTs. Surgical resection occurred in 1,233 patients and RFA was used in 1,302 patients. Surgical resection patients had significantly longer OS rates at 1, 3 and 5 years than RFA



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

(odds ratio [OR]: 0.60, 95% CI: 0.42 to 0.86, OR: 0.49, 95% CI: 0.36 to 0.65, and OR: 0.60, 95% CI: 0.43 to 0.84, respectively). When only HCC tumors \leq 3 cm were analyzed, resection was still significantly better in OS than RFA at 1-, 3- and 5-years. Recurrence rates were also significantly lower in the surgical resection group at 1, 3 and 5 years than RFA (OR: 1.48, 95% CI: 1.05 to 2.08, OR: 1.76, 95% CI: 1.49 to 2.08, and OR: 1.68, (95% CI: 1.21 to 2.34, respectively). Local recurrence rates did not differ significantly between procedures. Complication rates were higher with resection than RFA (OR: 6.25, 95% CI: 3.12 to 12.52; p = 0.000), but in a subanalysis of HCC \leq 3 cm, complication rates were significantly lower with resection than RFA.

Tiong and Maddern conducted a systematic review of the literature from 2000 to 2010 and a meta-analysis of survival and disease recurrence after RFA for HCC. Studies reporting on patients with HCC who were treated with RFA, either in comparison or in combination with other interventions, such as surgery or PEI, were eligible for inclusion. Outcome data collected were OS, disease-free survival and disease recurrence rates. Only RCTs, quasi-RCTs, and non-randomized comparative studies with more than 12 months' follow-up were included. Forty-three articles, including 12 RCTs, were included in the review. The majority of the articles reported the use of RFA for unresectable HCC, often in combination with other treatments such as PEI, transarterial chemoembolization, and/or surgery. A meta-analysis of 5 RCTs showed that RFA was better than PEI, with higher overall and disease-free survival rates. Data on RFA compared to microwave ablation were inconclusive. The authors concluded that RFA can achieve good clinical outcomes for unresectable HCC.

In a 2013 meta-analysis comparing RFA to cryoablation for HCC, Huang and colleagues evaluated 3 prospective studies and 1 retrospective study. Included in the studies were 180 RFA and 253 cryoablation patients. RFA was found to be significantly superior to cryoablation in rates of complications (OR: 2.80, 95% CI: 1.54-5.09), local recurrence of patient (OR: 4.02, 95% CI: 1.93-8.39), and local recurrence of tumor (OR: 1.96, 95% CI: 1.12-3.42). However, mortality was not significantly different (OR 2.21, 95% CI: 0.45-10.8) between groups.

Randomized controlled trials: In 2012, Feng et al. reported on a randomized controlled trial of 84 RFA patients compared to 84 surgical resection patients with up to 2 HCC nodules less than 4 cm in size. Patients were followed for 3 years and OS and recurrence-free survival were not statistically different between groups, (p = 0.342 and p = 0.122, respectively).

Radiofrequency Ablation in the Transplant Setting for Unresectable Hepatocellular Cancer

In 2002, the United Network for Organ Sharing (UNOS) introduced a new liver allocation system—model for endstage liver disease (MELD)—for adult patients awaiting liver transplant. The MELD score is a continuous disease severity scale incorporating bilirubin, prothrombin time (i.e., International Ratio for Prothrombin Activity [INR]), and creatinine into an equation, producing a number that ranges from 1 to 40. Aside from those in fulminant liver failure, donor livers are prioritized to those with the highest MELD number. This scale accurately predicts the risk of dying from liver disease except for those with HCC, who often have low MELD scores since bilirubin, INR, and creatinine levels are near normal.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

In considering how to allocate the scarce donor organs, UNOS sought to balance risk of death on the waiting list against risk of recurrence after transplant. Patients with T1 lesions were considered at low risk of death on the waiting list, while those with T3 lesions are at high risk of post-transplant recurrence. Patients with T2 tumors have an increased risk of dying while on the waiting list compared with those having T1 lesions and an acceptable risk of post-transplant tumor recurrence. Therefore, UNOS criteria prioritize T2 HCC by allocating additional points equivalent to a MELD score predicting a 15% probability of death within three months. The definition of T2 lesions are often referred to as the "Milan criteria," in reference to a key 1996 study that examined the recurrence rate of HCC according to the size of the initial tumor. Note that liver transplantation for those with T3 HCC is not prohibited, but these patients do not receive any priority on the waiting list. All patients with HCC awaiting transplantation are reassessed at 3-month intervals. Those whose tumors have progressed and are no longer T2 tumors will lose the additional allocation points.

Therefore, the UNOS allocation system provides incentives to use locoregional therapies in two different settings:

- To downsize T3 tumors to T2 status to meet the UNOS criteria for additional allocation points; or
- To prevent progress of T2 tumors while on the waiting list.

These two indications are discussed further here. It should be noted that the UNOS policy addresses the role of locoregional therapy in the pretransplant setting as follows:

Organ Procurement and Transplant Network (OPTN) Class 5T (Treated) nodules are defined as any OPTN Class 5 or biopsy-proven HCC lesion that was automatically approved upon initial application or extension and has subsequently undergone loco-regional treatment. OPTN Class 5T nodules qualify for continued priority points predicated on the pre-treatment classification of the nodule(s) and are defined as:

1. Past loco-regional treatment for HCC (OPTN class 5 lesion or biopsy proven prior to ablation).
2. Evidence of persistent/recurrent HCC such as nodular or crescentic extra-zonal or intra-zonal enhancing tissue on late arterial imaging (relative to hepatic parenchyma) may be present.

Organ Procurement and Transplant Network guidelines also indicate "candidates whose tumors have been ablated after previously meeting the criteria for additional MELD/Pediatric End-Stage Liver Disease (PELD) points (OPTN Class 5T) will continue to receive additional MELD/PELD points (equivalent to a 10-percentage point increase in candidate mortality) every 3 months without Regional Review Board (RRB) review, even if the estimated size of residual viable tumor falls below stage T2 criteria."

Candidates with HCC not meeting transplant criteria, "including those with downsized tumors whose original/presenting tumor was greater than a stage T2, must be referred to the applicable RRB for prospective review in order to receive additional priority."

Locoregional Therapy as a Technique to Prevent Tumor Progression While on the Waiting List

Several prior studies have reported drop-out rates of wait-listed patients treated with locoregional therapy. However, lacking controlled data, it is difficult to assess contributions of locoregional therapy to time on the waiting list. In addition, in 2002, as discussed above, UNOS revised its liver allocation policy, such that wait times for patients with HCC meeting the "Milan criteria" have now declined.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

The majority of the literature has focused either on TACE or a variety of locoregional therapies. Given these limitations, the following case series have been reported. Fisher and colleagues reported on 33 patients who received multimodality ablation therapy, consisting primarily of RFA or TACE. Five patients (12%) were removed from the waiting list after waits of 5 to 14 months. In this protocol, patients with tumors larger than 5 cm were not considered transplant candidates until the tumor was completely ablated using TACE, RFA, or another technique. Yamashiki and colleagues reported on 288 patients given various ablative therapies; the dropout rate due to tumor progression at 1 and 3 years was 6.2% and 23%, respectively. Tumors greater than 3 cm affected the dropout rate due to tumor progression. Mazzaferro et al. reported on 50 patients with HCC who underwent RFA while awaiting transplantation; no patient had to be removed from the waiting list due to tumor progression over a mean wait time of 9.5 months. The median tumor size was 3 cm, and 80% of patients met the Milan criteria. Similarly, Lu and colleagues reported on 52 patients who underwent RFA as a bridge to transplantation, 42 of whom met the Milan criteria. After a mean of 12 months, 5.8% had dropped off the waiting list due to tumor progression.

In a 2008 paper, Belghiti and colleagues reviewed the literature reporting efficacy of local management approaches including resection, TACE, RFA, and no treatment. They concluded that RFA can induce complete necrosis in the majority of small tumors (< 2.5 cm), and that there is no data demonstrating that the treatment reduces the rate of drop out before transplantation or improves the survival after transplant. None of the studies included data from U.S. centers for patients listed after adoption of the Milan criteria. Porrett et al. retrospectively compared 31 patients treated with RFA with 33 untreated (U) controls. Study endpoints included patient and disease-free survival, tumor recurrence, explant tumor viability, and the ability of magnetic resonance imaging (MRI) to detect viable tumor after therapy. Both cohorts had similar demographic, radiographic, and pathologic characteristics, although untreated patients waited longer for transplantation (119 [U] vs. 54 [RFA] days after MELD assignment) ($p = 0.05$). Only 20% of treated tumors demonstrated complete ablation (necrosis) as defined by histologic examination of the entire lesion. Only 55% of lesions with histologic viable tumor were detected by MRI after pretransplant therapy. After 36 months of follow-up, there was no difference between the treated and untreated groups in OS (84 vs. 91%), disease-free survival (74% vs. 85%), cancer recurrence (23% vs. 12%), or mortality from cancer recurrence (57% vs. 25% - all respectively) ($p > 0.1$). The authors concluded that viable tumor frequently persists after pretransplant locoregional therapy and neoadjuvant treatment does not appear to improve post-transplant outcomes in the current MELD era.

Current UNOS policy on allocation of livers indicates that candidates whose tumors have been ablated after meeting the criteria for additional MELD/PELD (PELD – calculator for persons under age 12 years) points will continue to receive additional points (equivalent to a 10% increase in mortality) every three months without review, even if the estimated size of residual viable tumor falls below stage T2 criteria. The policy also notes that candidates may be removed from the listing if they are determined to be unsuitable for transplantation based on progression of HCC.

Locoregional Therapies to Downgrade Hepatocellular Carcinoma Prior to Transplant Radiofrequency Ablation to Downstage Hepatocellular Carcinoma Prior to Transplant

Yao et al. analyzed longer-term outcome data on HCC downstaging in a cohort of 61 patients with tumor stage exceeding T2 criteria enrolled between June 2002 and January 2007. Eligibility criteria for



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

downstaging included: 1) one lesion larger than 5 cm and up to 8 cm; 2) 2 to 3 lesions with at least one lesion larger than 3 cm and not exceeding 5 cm, with total tumor diameter up to 8 cm; or 3) 4 to 5 lesions with none larger than 3 cm, with total tumor diameter up to 8 cm. TACE and laparoscopic RFA (LRFA) either alone or in combination were the main methods used: 11 patients received LRFA alone, 14 received TACE and LRFA, and 9 received TACE and percutaneous RFA. A minimum observation period of three months after downstaging was required before liver transplant. Tumor downstaging was successful in 43 patients (70.5%). Thirty-five patients (57.4%) received liver transplant, including two with live-donor liver transplantation. Treatment failure was observed in 18 patients (29.5%), primarily due to tumor progression. In the explant of 35 patients who underwent transplant, 13 had complete tumor necrosis, 17 met T2 criteria, and 5 exceeded T2 criteria. The Kaplan-Meier intention-to-treat survival at 1 and 4 years after downstaging were 87.5% and 69.3%, respectively. The 1-year and 4-year post-transplantation survival rates were 96.2% and 92.1%, respectively. No patient had HCC recurrence after a median post-transplantation follow-up of 25 months. The only factor predicting treatment failure was pretreatment alpha-fetoprotein greater than 1,000 ng/mL. From this small series, the authors conclude that successful downstaging can be achieved with excellent post-transplant outcomes.

A national conference involving transplant physicians was held to better characterize the long-term outcomes of liver transplantation for patients with HCC and to discuss the policy of assigning increased priority for candidates with stage T2 HCC on the transplant waiting list in the U.S. Goals of the conference were to standardize pathology reporting, develop specific imaging criteria, expand the Milan Criteria (the criteria used to measure tumor size to determine if a patient qualifies for transplant), discuss locoregional therapy, define criteria for downstaging transplantation, and review current liver allocation system for HCC patients. Pomfret and colleagues summarized the conference findings and recommendations.

The workgroup on locoregional therapy found compelling evidence that pretransplant locoregional therapy decreases waitlist dropout, especially for patients who wait longer than 3-6 months for transplant. They note "there is a paucity of data comparing RFA with transarterial therapies for the treatment of HCC prior to liver transplant and most single-center trials have a mixture of [locoregional therapies] included in the study population" and that, while early studies suggested a high rate of tumor seeding with percutaneous RFA, it is rare in larger series from experienced centers. The workgroup considering evidence to support expansion of MELD criteria for patients with HCC reported wide regional variation in the risk of death for patients without HCC. The "MELD score of the non-HCC patients was quite low in some regions. Post-transplant survival in HCC patients ranged from 25% in regions with few non-HCC patients with high MELD scores to greater than 70% in regions in which there was a greater need for liver transplant (higher MELD scores) in the non-HCC population." The workgroup observed that there is extreme variability of the time to transplantation of patients with HCC in the country suggesting that management of patients on the waitlist and outcomes may vary. In addition, "Concern has been raised that short times to liver transplant may lead to an increase in post-transplant recurrence because the tumor biology [aggressiveness] has not had enough time to be expressed. The lack of national data on recurrence rates limits one's ability to study this national experiment of nature based on the divergent waiting times for transplantation for HCC." There was agreement that the allocation policy should result in similar risks of removal from the waiting list and similar transplant rates for HCC and non-HCC candidates. In addition, the allocation policy should select HCC candidates so that there are similar post-transplant outcomes for HCC and non-HCC recipients. There was

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

a general consensus for the development of a calculated continuous HCC priority score for ranking HCC candidates on the list that would incorporate the calculated MELD score, alpha-fetoprotein, tumor size, and rate of tumor growth. Only candidates with at least stage T2 tumors would receive additional HCC priority points. The paper discusses pretransplant local regional therapy to allow patients to maintain transplant candidacy, as well as to downstage to meet MELD criteria. The workgroup on the role of downstaging in transplant candidates with HCC noted inconsistent outcomes reported in the literature and proposed a definition of downstaging that would include TACE and various ablative techniques but not resection. The group noted that only two regions have adopted a downstaging protocol.

Yao and colleagues reported on a case series of 30 patients with HCC who underwent locoregional therapy specifically to downstage tumors to meet the University of California San Francisco (UCSF) criteria. Eligibility for locoregional therapy seeking to downstage patients included either 1) 1 nodule between 5 and 8 cm in diameter; 2) 2 or 3 nodules with at least 1 between 3 and 5 cm in diameter, with a sum of diameters no greater than 8 cm; or 3) 4 or 5 nodules all less than or equal to 3 cm, with a sum of diameters less than 8 cm. Among the 30 patients, 21 (70%) met the criteria for locoregional therapy and 16 of these were successfully downstaged and underwent transplantation. No tumors recurred at a median follow-up of 16 months. The authors concluded that downstaging can be successfully achieved in most patients but that data regarding tumor recurrence requires longer follow-up.

Locoregional Therapies to Reduce Risk of Recurrence in Those with T3 tumors

An additional indication for locoregional therapies focuses on their use in patients with T3 tumors, specifically to reduce the incidence of recurrence post-transplant. If the incidence of recurrence can be reduced, then advocates have argued that the UNOS allocation criteria should not discriminate against patients with larger tumors. Certainly some patients with T3 lesions apparently are cured with liver transplant, although most experience recurrent tumor. For example, in the seminal 1996 study, the 4-year recurrence-free survival was 92% in those who met the "Milan criteria" compared to 59% in those who did not; additional studies confirm this difference in recurrence-free survival rate. However, other institutions have reported similar outcomes with expanded criteria. For example, Yao and colleagues at University of California at San Francisco reported similar recurrence-free survival after transplant in patients with T2 and a subset of those with T3 tumors. This T3 subset was defined as a single lesion \leq 6.5 cm or \leq 3 lesions with none greater than 3 cm and with a sum of tumor diameters \leq 8 cm. These expanded criteria are known as the UCSF criteria.

The question is whether locoregional therapies (including both RFA and chemoembolization) may decrease the recurrence rate in patients meeting the UCSF criteria. Yao and colleagues published a detailed analysis of 121 patients with HCC who underwent transplantation. Seventy-eight patients (64%) had T2 lesions, while an additional 27 patients (22.3%) met the expanded UCSF criteria, termed T3A lesions. The rest had T1, T3B, or T4 lesions. Individual patients received a variety of preoperative locoregional therapies, including TACE or ablative therapies, such as PEI, RFA, or combined therapies. A total of 38.7% of patients did not receive preoperative locoregional therapy. The 1- and 5-year recurrence-free survival was similar in those with T2 and T3A lesions, while the corresponding recurrence-free rates were significantly lower for those with T3B and T4 lesions.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

The authors also compared recurrence-free survival of those who did and did not receive locoregional therapy. For those with T2 lesions, the recurrence rates were similar whether or not the patient received locoregional therapy. However, for T3 lesions (including both T3A and T3B), the 5-year recurrence-free survival was 85.9% for those who received locoregional therapy compared to 51.4% in those who did not. When the data for T2 and T3 lesions were grouped together, the 5-year recurrence-free survival was 93.8% for those who received locoregional therapy compared to 80.6% in those who did not. The authors concluded that preoperative locoregional therapy may confer a survival benefit in those with T2 or T3 lesions.

The authors note several limitations to the study, including the retrospective nature of the data and the marginal statistical significance of the improved survival given the small numbers of patients in each subgroup. For example, only 19 patients were in the T3A (i.e., UCSF expanded criteria) subgroup. In addition, no protocol specified which type of locoregional therapy to offer different patients. These therapies are only offered to those patients with adequate liver reserve; such patients may have an improved outcome regardless of the preoperative management.

Radiofrequency Ablation as a Primary Treatment of Unresectable Liver Metastases from Colorectal Cancer

More than half of patients with CRC will develop liver metastases, generally with a poor prognosis. A median survival of 21 months has been observed in patients with a single CRC liver metastasis; those with several unilobar lesions have median survival of 15 months; and, those with disseminated metastases have median survival of less than one year. A number of first-line systemic chemotherapy regimens have been used to treat metastatic CRC, with a 2-year survival rate of 25% for those treated with 5-fluorouracil (5-FU) or 5-FU plus leucovorin. With the introduction of newer agents, including irinotecan and oxaliplatin, and targeted drugs such as cetuximab and bevacizumab, 2-year survival rates have increased to 30–39%, with marked improvement in OS duration. As the liver is often the only site of metastases from CRC, however, locoregional therapies have been investigated. Surgical resection is considered the gold standard for treatment of CRC liver metastases, with 5-year actuarial survival rates that historically range from 28% to 38% but may reach 58% in appropriately selected, resectable patients without widely disseminated disease. However, only 10–25% of patients with CRC metastases are eligible for surgical resection because of the extent and location of the lesions within the liver or because of the presence of comorbid conditions or disseminated disease. Unresectable cases or those for whom surgery is contraindicated typically are treated with systemic chemotherapy, with poor results and considerable adverse side effects.

Alternatively, RFA has been proposed as an approach to treat metastatic CRC in the liver. Early clinical experience with RFA comprised case series to establish feasibility, safety, tolerability, and local therapeutic efficacy in short-term follow-up. A 2006 literature review encompassing six case series (N = 446) showed that RFA of unresectable CRC metastases was associated with 1-, 2-, and 3-year survival rates that ranged from 87–99%, 69–77%, and 37–58%, respectively. While these results suggest RFA may have clinical benefit in this setting, a primary caveat is the definition of the term “unresectable” in the different series, and that different surgeons may have different opinions on this issue. Further, differences in lesion size, number, distribution, prior treatments, RFA technology, and physician experience may affect results, making it difficult to compare results of different studies.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

Systematic Reviews: A 2012 systematic review by Cirocchi et al. analyzed 17 nonrandomized studies and one abstract on a RCT from a 2010 American Society of Clinical Oncology (ASCO) meeting on RFA for CRC liver metastases. The RCT reported progression-free survival was significantly higher in 60 patients receiving RFA plus chemotherapy when compared to 59 patients receiving only chemotherapy. The RCT did not report OS. This Cochrane review found different types of vulnerability in all reviewed studies. Of main concern was the imbalance of patient characteristics in the studies reviewed, as well as heterogeneity in the interventions, comparisons and outcomes. Therefore the authors concluded the evidence was insufficient to recommend RFA for CRC liver metastasis.

In 2013, Weng and colleagues reported on a systematic review and meta-analysis to compare RFA to liver resection for the treatment of CRC liver metastases. One prospective study and 12 retrospective studies were included in the analysis. Overall survival at 3 and 5 years was significantly longer in liver resection than RFA (risk ratio [RR]: 1.377, 95% CI: 1.246-1.522 and RR: 1.474, 95% CI: 1.284-1.692, respectively). Disease-free survival was also significantly longer in liver resection than RFA at 3 and 5 years (RR: 1.735, 95% CI: 1.483-2.029 and RR: 2.227, 95% CI: 1.823-2.720). While postoperative morbidity with liver resection was significantly higher than with RFA (RR: 2.495, 95% CI: 1.881-3.308), mortality was not significantly different between liver resection and RFA. Liver resection also still performed significantly better than RFA when data were analyzed in 3 subgroups: tumors < 3 cm, solitary tumor and open or laparoscopic approach. However, hospital stays were significantly shorter (9.2 ± 0.6 vs. 3.9 ± 0.4 , $p < 0.01$) and rates of complications lower (18.3% vs. 3.9%, $p < 0.01$) with RFA over liver resection. Interpretation of the meta-analysis is limited by the retrospective nature of the majority of studies.

A 2011 systematic review by Pathak and colleagues assessed the long-term outcome and complication rates of various ablative therapies used in the management of colorectal liver metastases. The literature search was from 1994 to 2010, and study inclusion criteria included a minimum 1-year follow-up and greater than 10 patients. In all, 226 potentially relevant studies were identified, 75 of which met the inclusion criteria. The majority of the studies were single-arm, single-center, retrospective and prospective. There was wide variability in patient groups, adjuvant therapies, and management approaches within individual studies. Several studies combined results for colorectal and non-colorectal metastases, often reporting combined outcomes. Endpoints were not always reported uniformly, with varying definitions of survival time, recurrence time, and complication rates. Cryotherapy (26 studies) had local recurrence rates of 12-39%, with mean 1-, 3- and 5-year survival rates of 84%, 37% and 17%, respectively. The major complication rate ranged from 7% to 66%. Microwave ablation (13 studies) had a local recurrence rate of 5-13%, with a mean 1-, 3- and 5-year survival of 73%, 30% and 16%, respectively, and a major complication rate ranging from 3% to 16%. Radiofrequency ablation (36 studies) had a local recurrence rate of 10-31%, with a mean 1-, 3- and 5-year survival of 85%, 36% and 24%, respectively, with major complication rate ranging from 0% to 33%. The authors concluded that ablative therapies offer significantly improved survival compared with palliative chemotherapy alone with 5-year survival rates of 17-24%, and that complication rates of commonly used techniques are low.

A review by Guenette and Dupuy in 2010 summarized the literature on the use of RFA for colorectal hepatic metastases. Approximately 17 studies in the literature with greater than 50 patients treated with RFA for colorectal hepatic metastases reported survival. Average tumor size, reported in 15 studies ranged from 2.1



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

cm-4.2 cm. Five-year OS, reported in 12 studies, ranged from 2% to 55.3% with a mean of 24.5%. The largest study series included in the review was by Lencioni et al. and consisted of 423 patients with average tumor size of 2.7 cm, 4 or fewer metastases, each 5 cm or less in greatest dimension, and no extrahepatic disease. Overall survival in the Lencioni et al. study at 1, 3 and 5 years was 86%, 47% and 24%, respectively. The authors of the Guenette/Dupuy review concluded that 5-year survival rates following RFA appear to rival those following resection but that long-term data associated with RFA and colorectal hepatic metastases are sparse, randomized trials have failed recruitment, and patients with resectable disease should undergo resection if possible. However, given the efficacy of RFA as compared to chemotherapy alone, RFA should be considered as a primary treatment option in patients with unresectable disease.

Cohort Studies: Prospective studies in which RFA was compared with resection or systemic chemotherapy in well-defined consecutive cohorts of patients with localized CRC metastases and no evidence of additional metastatic disease have been conducted. In the first study, Abdalla and coworkers examined recurrence and survival rates for clinically similar patients treated with hepatic resection only (n = 190), resection plus RFA (n = 101), RFA only (n = 57, open laparotomy by hepatobiliary surgeon), and systemic chemotherapy alone (n = 70). In the key relevant comparison, RFA versus chemotherapy in chemotherapy-naïve patients with non-resectable CRC metastases (median 1 lesion per patient, range 1-8, median tumor size 2.5 cm), OS at four years was 22% in the RFA group compared with 10% in the chemotherapy group (p = 0.005). Median survival was estimated at 25 months in the RFA group and 17 months in the chemotherapy group (p not reported). Recurrence anywhere in the liver at median follow-up of 21 months was 44% in the RFA group and 11% in the resection-only group (p < 0.001), although the proportion of patients with distant recurrence as a component of failure was similar (41% resection, 40% RFA, p not significant).

In a second trial, a consecutive series of well-defined, previously untreated patients (n = 201) without extrahepatic disease underwent laparotomy to determine therapeutic approach. Three groups were identified: those amenable to hepatic resection (n = 117); those for whom resection plus local ablation were indicated (RFA, n = 27; cryoablation, n = 18); and those deemed unresectable and unsuitable for local ablation (n = 39) who received systemic chemotherapy. Median OS was 61 months (95% CI: 41–81 months) in resected patients (median 1 tumor per patient, range 1–9, median diameter 3.8 cm), 31 months (95% CI: 20–42 months) in locally ablated patients (median 4 tumors per patient, range 1–19, median diameter 3 cm per lesion), and 26 months (95% CI: 17–35 months) in the chemotherapy patients (median 4 tumors per patient, range 1–17, median diameter 4 cm per lesion, p not significant, ablated vs. chemotherapy). Results from two validated quality-of-life instruments (EuroQol-5D and EORTC QLQ C-30) showed that patients treated by local ablation returned to baseline values within three months, whereas those treated with chemotherapy remained significantly lower (i.e., worse quality of life) than baseline over 12 months post-treatment (p < 0.05).

In 2011, van Tilborg and colleagues reported long-term results in 100 patients with unresectable colorectal liver metastases who underwent a total of 126 RFA sessions (237 lesions). Lesion size ranged from 0.2-8.3 cm (mean 2.4 cm). The mean follow-up time was 29 months (range 6-93 months). Major complications (including abscess, hemorrhage, grounding pad burns and diaphragm perforation) occurred in eight patients. Factors that determined the success of the procedure included lesion size and the number and



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

location of the lesions. Local tumor site recurrence was 5.6% for tumors less than 3 cm, 19.5% for tumors 3-5 cm, and 41.2% for those greater than 5 cm. Centrally located lesions recurred more often than peripheral ones, at 21.4% versus 6.5%, respectively, $p = 0.009$. Mean survival time from the time of RFA was 56 months (95% CI: 45-67 months).

A review by Guenette and Dupuy in 2010 summarized the literature on the use of RFA for colorectal hepatic metastases. Approximately 17 studies in the literature with greater than 50 patients treated with RFA for colorectal hepatic metastases reported survival. Average tumor size, reported in 15 studies ranged from 2.1 cm-4.2 cm. Five-year OS, reported in 12 studies, ranged from 2% to 55.3% with a mean of 24.5%. The largest study series included in the review was by Lencioni et al. and consisted of 423 patients with average tumor size of 2.7 cm, 4 or fewer metastases, each 5 cm or less in greatest dimension, and no extrahepatic disease. Overall survival in the Lencioni et al. study at 1, 3 and 5 years was 86%, 47% and 24%, respectively. The authors of the Guenette/Dupuy review concluded that 5-year survival rates following RFA appear to rival those following resection but that long-term data associated with RFA and colorectal hepatic metastases is sparse, randomized trials have failed recruitment, and patients with resectable disease should undergo resection if possible. However, given the efficacy of RFA as compared to chemotherapy alone, RFA should be considered as a primary treatment option in patients with unresectable disease.

A 2011 systematic review by Pathak and colleagues assessed the long-term outcome and complication rates of various ablative therapies used in the management of colorectal liver metastases. The literature search was from 1994 to 2010, and study inclusion criteria included a minimum 1-year follow-up and greater than 10 patients. In all, 226 potentially relevant studies were identified, 75 of which met the inclusion criteria. The majority of the studies were single-arm, single-center, retrospective and prospective. There was wide variability in patient groups, adjuvant therapies, and management approaches within individual studies. Several studies combined results for colorectal and non-colorectal metastases, often reporting combined outcomes. Endpoints were not always reported uniformly, with varying definitions of survival time, recurrence time, and complication rates. Cryotherapy (26 studies) had local recurrence rates of 12-39%, with mean 1-, 3- and 5-year survival rates of 84%, 37% and 17%, respectively. The major complication rate ranged from 7% to 66%. Microwave ablation (13 studies) had a local recurrence rate of 5-13%, with a mean 1-, 3- and 5-year survival of 73%, 30% and 16%, and a major complication rate ranging from 3% to 16%. Radiofrequency ablation (36 studies) had a local recurrence rate of 10-31%, with a mean 1-, 3- and 5-year survival of 85%, 36% and 24%, respectively, with major complication rate ranging from 0% to 33%. The authors concluded that ablative therapies offer significantly improved survival compared with palliative chemotherapy alone with 5-year survival rates of 17-24%, and that complication rates of commonly used techniques are low.

Radiofrequency Ablation as a Treatment of Unresectable Liver Metastases from Neuroendocrine Tumors

Most reports of radiofrequency treatment of neuroendocrine liver metastases include small numbers of patients or subsets of patients in reports of more than one ablative method or very small subsets of larger case series of patients with various diagnoses.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

Berber and Siperstein analyzed a large series of liver tumors treated with RFA. Of 1,032 tumors in the study, 295 were neuroendocrine tumor metastases. The mean number of lesions treated was 5.6 (range: 1-16) and mean size was 2.3 cm (range: 0.5-10.0 cm). Local recurrence rates were lower in patients with neuroendocrine tumors than in patients with other tumor types; neuroendocrine tumors (19/295, 6%), colorectal metastases (161/480, 24%), noncolorectal, nonneuroendocrine metastases (28/126, 22%), and HCC (23/131, 18%). In patients with neuroendocrine tumors, 58% of the recurrences were evident at one year and 100% at two years versus 83% at one year and 97% at two years for colorectal metastases. Eight neuroendocrine tumors were eligible for repeat RFA; seven were retreated and one was not. Symptom control and survival were not reported in this study.

Mazzaglia et al. report on a series gathered over ten years of 63 patients with neuroendocrine metastases who were treated with 80 sessions of LRFA. Tumor types were 36 carcinoid, 18 pancreatic islet cell, and 9 medullary thyroid cancer. Indications for enrollment in the study were liver metastases from neuroendocrine tumors, enlarging liver lesions, worsening of symptoms, and/or failure to respond to other treatment modalities, and predominance of disease in the liver; however, patients with additional minor extrahepatic disease were not excluded from the study. RFA was performed 1.6 years (range, 0.1-7.8 years) after diagnosis of liver metastases. Fourteen patients had repeat sessions for disease progression. The mean number of lesions treated at the first RFA session was six and the mean tumor size was 2.3 cm. One week after surgery, 92% of patients had at least partial symptom relief and 70% had complete relief. Symptom control lasted 11 +/- 2.3 months. Median survival times were 11 years postdiagnosis of primary tumor, 5.5 years postdiagnosis of neuroendocrine hepatic metastases, and 3.9 years postfirst RFA treatment.

Elias et al. report on 16 patients who underwent a one-step procedure comprising a combination of hepatectomy and RFA for treatment of gastroenteropancreatic endocrine tumors. A mean of 15 +/- 9 liver tumors per patient were surgically removed, and a mean of 12 +/- 8 were ablated using RFA. Three-year survival and disease-free survival rates were similar to those observed in the authors' preliminary series of 47 patients who had hepatectomy with a median of 7 liver tumors per patient. Venkatesan and colleagues report on six patients treated for pheochromocytoma metastases. Complete ablation was achieved in 6 of 7 metastases. Mean follow-up was 12.3 months (range: 2.5-28 months).

Radiofrequency Ablation as a Primary Treatment of Unresectable Liver Metastases from Tumors other than Colorectal Cancer and Neuroendocrine Tumors

Breast Cancer

A number of case series report RFA of breast cancer liver metastases. In a retrospective review, Meloni et al. assessed local control and intermediate- and long-term survival in 52 patients. Inclusion criteria were fewer than five tumors, maximum tumor diameter of 5 cm or smaller, and disease confined to the liver or stable with medical therapy. Complete tumor necrosis was achieved in 97% of tumors. Median time to follow-up from diagnosis of liver metastasis and from RFA was 37.2 and 19.1 months, respectively. Local tumor progression occurred in 25% of patients, and new intrahepatic metastases developed in 53%. Overall median survival time, from the time the first liver metastasis was diagnosed, was 42 months, and 5-year survival was 32%. Patients with tumors 2.5 cm in diameter or larger had a worse prognosis than those with smaller tumors. The authors conclude that these survival rates are comparable to those reported in the literature for surgery or laser ablation. In another series of 43 breast cancer patients with 111 liver



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

metastases, technical success was achieved in 107 metastases (96%). During follow-up, local tumor progression was observed in 15 metastases. The estimated overall median survival was 58.6 months. Survival was significantly lower among patients with extrahepatic disease, with the exception of skeletal metastases.

A series of 19 patients was reported by Lawes et al. Eight patients had disease confined to the liver, with 11 also having stable extrahepatic disease. At the time of the report, 7 patients, with disease confined to the liver at presentation, were alive, as were 6 with extra-hepatic disease; median follow-up after RFA was 15 months (range: 0-77 months). Survival at 30 months was 41.6%. RFA failed to control hepatic disease in three patients.

Other reports include 16 or fewer subjects. All of the authors report that RFA of breast cancer liver metastases is technically feasible and may provide a survival benefit in woman without extra-hepatic or stable extrahepatic disease (excluding bone metastases).

Sarcoma

Jones et al. evaluated RFA in a series of patients with sarcoma. Thirteen gastrointestinal stromal tumor (GIST) patients and 12 with other histological subtypes received RFA for metastatic disease in the liver: 12 of these responded to the first RFA procedure and 1 achieved stable disease. Two GIST patients received RFA on two occasions to separate lesions within the liver, and both responded to the second RFA procedure. Of the other subtypes: 7 underwent RFA to liver lesions, 5 of these responded to RFA, 1 progressed and 1 was not assessable for response at the time of analysis. RFA was well-tolerated in this series of sarcoma patients. RFA may have a role in patients with GIST who have progression in a single metastasis but stable disease elsewhere. The authors advise that further larger studies are required to better define the role of this technique in this patient population.

A case series of 66 patients who underwent hepatic resection (n = 35), resection and RFA (n = 18), or RFA alone (n = 13) was reported by Pawlik et al. After a median follow-up of 35.8 months, 44 patients had recurrence (intrahepatic only, n = 16; extrahepatic only, n = 11; both, n = 17). The 1-, 3-, and 5-year OS rates were 91.5%, 65.4%, and 27.1%, respectively. The authors recommend that patients with metastatic disease who can be rendered surgically free of disease be considered for potential hepatic resection.

Ongoing Clinical Trials

A search of online site ClinicalTrials.gov in June 2013 identified 8 ongoing Phase 3 and 4 trials on RFA of the liver for HCC and CRC liver metastases.

Summary

In RFA, a probe that generates heat is inserted into the center of a tumor resulting in a 3- to 5-cm sphere of dead tissue. The cells killed by RFA are not removed but are gradually replaced by fibrosis and scar tissue. If there is local recurrence, it occurs at the edge, and in some cases may be retreated. Radiofrequency ablation may be performed percutaneously, laparoscopically, or as an open procedure.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

For treating patients with unresectable HCC, numerous studies including randomized trials demonstrate that in patients with small foci of HCC (no more than three lesions), RFA appears to be better than ethanol injection in achieving complete ablation and preventing local recurrence. Three-year survival rates of 80% have been reported. Thus, the policy statement notes that this indication for RFA in patients with HCC who are not candidates for resection or transplant may be considered medically necessary.

A substantial body of literature has been published on the use of RFA to treat CRC metastases in the liver. Two prospective studies comprise good evidence that OS following RFA is at least equivalent and likely better than that obtained with currently accepted systemic chemotherapy in well-matched patients with unresectable hepatic metastatic CRC who do not have extrahepatic disease. Additional evidence from one comparative study suggests RFA has a lesser deleterious effect on quality of life than chemotherapy and that RFA patients recover quality of life significantly faster than chemotherapy recipients. Quicker recovery of quality of life may be viewed as a net health benefit when viewed in the context of expected survival durations of patients with metastatic cancer. In addition, results from a number of uncontrolled case series also suggest RFA of hepatic CRC metastases produces long-term survival that is at minimal equivalent and likely superior to historical outcomes achieved with systemic chemotherapy. Although indirect comparisons of series results are difficult, the body of data shows consistent change in direction and magnitude of effect that suggests an RFA benefit. It should be recognized, however, that patients treated with RFA in different series may have better prognosis than those who undergo chemotherapy, suggesting patient selection bias may at least partially explain the apparent better outcomes observed following RFA. Given the caveats outlined above, the available body of clinical evidence is sufficient to conclude that RFA of unresectable CRC metastases to the liver, absent extrahepatic metastatic disease, may be considered medically necessary according to the Clinical Guidelines noted above.

Evidence shows that durable tumor and symptom control of neuroendocrine liver metastases can be achieved by RFA. This evidence is based on case series; neuroendocrine tumors are uncommon. Thus, a statement indicating that RFA of hepatic metastases of neuroendocrine tumors may be considered medically necessary in patients whose symptoms are not controlled by systemic therapy has been added.

Transplant clinicians find the evidence compelling that use of locoregional therapy reduces the dropout rate of patients with HCC awaiting a liver transplant. After listing for transplant, UNOS does not reassign status based on tumor shrinkage from locoregional therapy. A number of approaches are accepted for use in this situation, including TACE and RFA. Small case series conclude that patients managed on the transplant list with locoregional therapy have outcomes comparable to patients who do not receive pretransplant treatment. However, earlier liver transplant for HCC patients may reduce the need for RFA in this situation. Thus, given the strong clinical support, UNOS position, and clinical studies, the coverage statement has been changed to indicate that RFA may be considered medically necessary as a bridge to liver transplant.

Currently, there is less evidence available for patients treated with RFA to specifically downsize (downstage) tumors (tumors of stage greater than T2) to meet priority transplant criteria, and its use for this application is considered investigational.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

The published evidence for demonstrating improved health outcomes with RFA of other hepatic metastatic tumors (e.g., breast cancer and sarcoma) is lacking. Comparative trials are needed for these malignancies that may have associated systemic disease. Use of RFA in these tumors is considered investigational under this policy; the data are insufficient to change this coverage statement.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, "Radiofrequency Ablation of Primary or Metastatic Liver Tumors", 7.01.91, 7:2013.
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Radiofrequency ablation of unresectable hepatic tumors. TEC Assessments 2003: Volume 18, Tab 13.
3. McWilliams JP, Yamamoto S, Raman SS et al. Percutaneous ablation of hepatocellular carcinoma: current status. *J Vasc Interv Radiol* 2010; 21(8 suppl):S204-13.
4. Cho YK, Kim JK, Kim MY et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. *Hepatology* 2009; 49(2):453-9.
5. Shen A, Zhang H, Tang C et al. A systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. *J Gastroenterol Hepatol* 2013; 28(5):793-800.
6. Xu G, Qi FZ, Zhang JH et al. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. *World J Surg Oncol* 2012; 10:163.
7. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. *Br J Surg* 2011; 98(9):1210-24.
8. Huang YZ, Zhou SC, Zhou H et al. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. *Hepatogastroenterology* 2013; 60(127).
9. Feng K, Yan J, Li X et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *J Hepatol* 2012; 57(4):794-802.
10. Organ Procurement and Transplant Network. Organ Distribution: Allocation of Livers (3.6.4.4). Available online at: http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf.
11. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; 334(11-Jan):693-9.
12. Fisher RA, Maluf D, Cotterell AH et al. Non-resective ablation therapy for hepatocellular carcinoma: Effectiveness measured by intention to treat and dropout from liver transplant waiting list. *Clin Transplant* 2004; 18(5):502-12.
13. Yamashiki N, Tateishi R, Yoshida H et al. Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for liver transplantation. *Liver Transpl* 2005; 11(5):508-14.
14. Mazzaferro V, Battiston C, Perrone S et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. *Ann Surg* 2004; 240(5):900-9.
15. Lu DS, Yu NC, Raman SS et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. *Hepatology* 2005; 41(5):1130-7.
16. Belghiti J, Carr BI, Greig PD et al. Treatment before liver transplantation for HCC. *Ann Surg Oncol* 2008; 15(4):993-1000.
17. Porrett PM, Peterman H, Rosen M et al. Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. *Liver Transpl* 2006; 12(4):665-73.
18. Yao FY, Kerlan RK, Jr., Hirose R. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. *Hepatology* 2008; 48(3):819-27.
19. Pomfret EA, Washburn K, Wald C. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. *Liver Transpl* 2010; 16(3):262-78.
20. Yao FY, Hirose R, LaBerge JM et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. *Liver Transpl* 2005; 11(12):1505-14.
21. Sauer P, Kraus TW, Schemmer P et al. Liver transplantation for hepatocellular carcinoma: is there evidence for expanding the selection criteria? *Transplantation* 2005; 80(1 Suppl):S105-8.
22. Fernandez JA, Robles R, Marin C et al. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? *Transplant Proc* 2003; 35(5):1818-20.
23. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. *Liver Transpl* 2002; 8(9):765-74.
24. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; 33(6):1394-403.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

25. Merli M, Nicolini G, Gentili F et al. Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. *Transplant Proc* 2005; 37(6):2535-40.
26. Yao FY, Kinkhabwala M, LaBerge JM et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. *Am J Transplant* 2005; 5(4 pt 1):795-804.
27. Kemeny N. Management of liver metastases from colorectal cancer. *Oncology (Williston Park)* 2006; 20(10):1161-76.
28. McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. *Br J Surg* 2006; 93(10):1192-202.
29. Lencioni R, Crocetti L, Cioni D et al. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. *Invest Radiol* 2004; 39(11):689-97.
30. Cirocchi R, Trastulli S, Boselli C et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. *Cochrane Database Syst Rev* 2012; 6:CD006317.
31. Weng M, Zhang Y, Zhou D et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. *PLoS One* 2012; 7(9):e45493.
32. Pathak S, Jones R, Tand JMF et al. Ablative therapies for colorectal liver metastases: a systematic review. *Colorectal Dis* 2011; 13(9):e252-65.
33. Guenette JP, Dupuy DE. Radiofrequency ablation of colorectal hepatic metastases. *J Surg Oncol* 2010; 102(8):978-87.
34. Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004; 239(6):818-27.
35. Ruers TJ, Joosten JJ, Wiering B et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal metastases: a prospective study. *Ann Surg Oncol* 2007; 14(3):1161-9.
36. Van TAA, Meijerink MR, Sietses C et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. *Br J Radiol* 2011; 84(1002):556-65.
37. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: An analysis of 1032 tumors. *Ann Surg Oncol* 2008; 15(10):2757-64.
38. Mazzaglia PJ, Berber E, Milas M et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. *Surgery* 2007; 142(1):10-9.
39. Elias D, Goere D, Leroux G et al. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. *Eur J Surg Oncol* 2009; 35(10):1092-7.
40. Venkatesan AM, Locklin J, Lai EW et al. Radiofrequency ablation of metastatic pheochromocytoma. *J Vasc Interv Radiol* 2009; 20(11):1483-90.
41. Meloni MF, Andreano A, Laeseke PF et al. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation—intermediate and long-term survival rates. *Radiology* 2009; 253(3):861-9.
42. Jakobs TF, Hoffmann RT, Schrader A et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. *Cardiovasc Interv Radiol* 2009; 32(1):38-46.
43. Lawes D, Chopada A, Gillams A et al. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. *Ann R Coll Surg Engl* 2006; 88(7):639-42.
44. Jones RL, McCall J, Adam A et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. *Eur J Surg Oncol* 2010; 36(5):477-82.
45. Pawlik TM, Vauthey JN, Abdalla EK et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. *Arch Surg* 2006; 141(6):537-44.

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2013 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT,



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	47370, 47380, 47382, 76940, 77013, 77022
HCPCS	No codes
ICD-9 Diagnosis	155.0, 155.2, 197.7, 209.72
ICD-9 Procedure	50.23, 50.24, 50.25, 50.26, 50.29

Policy History

Original Effective Date: 09/22/2005
Current Effective Date: 01/15/2014

09/07/2005 Medical Director review
09/20/2005 Medical Policy Committee review
09/22/2005 Quality Care Advisory Council approval
07/07/2006 Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.
01/10/2006 Medical Director review
01/17/2006 Medical Policy Committee approval. Coverage eligibility updated to include investigational status of RFA as a bridge to liver transplant.
01/09/2008 Medical Director review
01/23/2008 Medical Policy Committee approval. Added "in the absence of extrahepatic metastatic disease" to the patient selection criteria.
01/07/2009 Medical Director review
01/14/2009 Medical Policy Committee approval. No change to coverage eligibility.
01/07/2010 Medical Policy Committee approval
01/20/2010 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/06/2011 Medical Policy Committee review
01/19/2011 Medical Policy Implementation Committee approval. Extensively revised coverage statements and added policy guidelines.
01/06/2011 Medical Policy Committee review
01/19/2011 Medical Policy Implementation Committee approval. Rationale revised. No change to coverage.
03/01/2012 Medical Policy Committee review
03/21/2012 Medical Policy Implementation Committee approval
01/03/2013 Medical Policy Committee review
01/09/2013 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/09/2014 Medical Policy Committee review
01/15/2014 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 01/2015

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Policy # 00182

Original Effective Date: 09/22/2005

Current Effective Date: 01/15/2014

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 2. credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. reference to federal regulations.

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. in accordance with nationally accepted standards of medical practice;
- B. clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.